PEOPLE - Targeted Diagnostics & Therapeutics (TDT) makes appointment:
This article was originally published in Clinica
Targeted Diagnostics & Therapeutics (TDT), developer of molecular-based technologies for the targeted detection, diagnosis and treatment of gastrointestinal cancers and infectious diseases, has appointed Daniel O'Shannessy to the newly-created position of COO. He will be responsible for directing the West Chester, Pennsylvania-based firm's clinical and business expansion, as well as overseeing the strategic growth of new products and technologies. Dr O'Shannessy joins TDT from Gen-Probe, where he served as senior director of strategic planning for the oncology diagnostics division.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.